
Kenneth Cardona/winshipcancer.emory.edu
May 1, 2025, 17:01
Ken Cardona leads EA7211/STRASS 2 clinical trial: A randomized study in retroperitoneal sarcoma – ECOG-ACRIN Cancer Research Group
ECOG-ACRIN Cancer Research Group, shared a post on X:
“Clinical Trial EA7211/STRASS 2, led in the US by Ken Cardona, is the second randomized study ever performed in retroperitoneal soft tissue sarcoma and is enrolling patients in the US, Europe, Canada, Australia, New Zealand, and Japan!”
Learn more about retroperitoneal sarcoma on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 16:36
May 1, 2025, 16:32
May 1, 2025, 16:20